US Patent Issued to The Trustees of the University of Pennsylvania on Feb. 24 for "Mullerian inhibiting substance type 2 receptor (MISIIR)-specific CAR T cells for the treatment of ovarian cancer and other gynecologic malignancies" (Pennsylvania Inventors)

ALEXANDRIA, Va., Feb. 24 -- United States Patent no. 12,559,563, issued on Feb. 24, was assigned to The Trustees of the University of Pennsylvania (Philadelphia).

"Mullerian inhibiting substance type 2 receptor (MISIIR)-specific CAR T cells for the treatment of ovarian cancer and other gynecologic malignancies" was invented by Daniel J. Powell (Bala Cynwyd, Pa.) and Alba Rodriguez-Garcia (Philadelphia).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides modified immune cells or precursors thereof (e.g., modified T cells) comprising a chimeric antigen receptor (CAR) having affinity for Mullerian inhibiting substance type 2 receptor (MISIIR). Compositions and methods of treatment of d...